Here's Why You Should Hold Cencora Stock in Your Portfolio Now

Cencora (COR) is poised for continued growth, fueled by strong performance in its U.S. Healthcare Solutions segment, which reported a 12.2% year-over-year revenue increase to $67.2 billion in Q3 FY24, and robust demand for specialty products, particularly GLP-1 drugs. The company recently raised its fiscal 2024 adjusted EPS guidance to $13.55-$13.65, signaling operational strength and the impact of strategic share repurchases. Despite these tailwinds and its broad distribution network, Cencora faces significant competitive pressures within the pharmaceutical distribution market.

Analysis

Cencora, Inc. (COR) demonstrates strong operational momentum, primarily driven by its U.S. Healthcare Solutions segment, which reported a 12.2% year-over-year revenue increase to $67.2 billion in the third quarter of fiscal 2024. This growth is largely fueled by robust demand for specialty products, particularly GLP-1 drugs, which has led the company to project 12-13% revenue growth for the segment in fiscal 2024. Management's confidence is further underscored by an upward revision of its full-year adjusted EPS guidance to a range of $13.55-$13.65, supported by a recent $400 million share repurchase from Walgreens. This operational strength is reflected in positive analyst estimate revisions, with the fiscal 2024 consensus EPS rising to $13.62. Despite these positive indicators and a 10.3% year-to-date share price increase that outpaces the industry, the company's stock lags the S&P 500. The primary headwind remains the highly competitive nature of the pharmaceutical distribution market, which poses a persistent risk to market share and margins.

Key Decisions for Investors

• Investors should monitor the growth trajectory and margin contribution of specialty drugs, especially the GLP-1 category, as this is the key driver underpinning Cencora's raised revenue and earnings guidance.
• The combination of a $400 million share buyback and raised EPS guidance presents a bullish signal, but this should be weighed against the intense and ongoing competitive pressures which could erode profitability over the long term.
• Given the stock's outperformance against its industry but underperformance relative to the S&P 500, investors should assess whether the current valuation adequately prices in the company's solid execution and double-digit growth forecasts versus the noted market risks.